Compare Adaptive Biotechnologies Corp (ADPT) vs Roblox Corp (RBLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Roblox Corp — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Roblox Corp trades at $35.61 (market cap $25.87B). The key difference: Roblox Corp is far larger — about 6.4× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Roblox Corp nearer its low. Which is the better fit depends on your goals.
| ADPT | RBLX | |
|---|---|---|
Market Cap | $4.04B | $25.87B |
Sector | Health | Media |
52-Week High | $25.45 | $141.56 |
52-Week Low | $12.30 | $35.60 |
Enterprise Value | $4.10B | $24.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
RBLX trades at $35.76, down 3.48% in the last session, with a bearish technical outlook from moving averages. The company reported revenue growth to $4.89 billion in 2025 but remains unprofitable, with a net loss of $1.07 billion. Analyst consensus is mixed, with a $45.67 price target, while recent news highlights multiple class-action lawsuits filed against the company.
The outlook is clouded by persistent losses and legal challenges, though revenue growth and strong operating cash flow of $1.80 billion offer some fundamental support. Risks include profitability challenges and litigation, but the stock may appeal to growth-oriented investors if execution improves and losses narrow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →
